DUBLIN–(BUSINESS WIRE)–Research and Markets has actually announced the addition of the “Refractory Acute Myeloid Leukemia – Pipeline Review, H1 2016” report to their offering.
This report offers comprehensive post regard the therapeutic progress with Refractory Acute Myeloid Leukemia, finish along with comparative analysis at numerous stages, therapeutics assessment by drug target, mechanism of action (MoA), course of administration (RoA) and molecule type, along along with latest updates, and featured news and press releases. It additionally reviews essential users associated with the therapeutic progress with Refractory Acute Myeloid Leukemia and unique features regard late-phase and discontinued projects.
The report improves decision-making capabilities and aids to produce efficient contrarily strategies to obtain competitive advantage. It strengthens R&D pipelines by determining brand-new targets and MOAs to make first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Refractory Acute Myeloid Leukemia Overview
- Therapeutics Development
- Pipeline product and services with Refractory Acute Myeloid Leukemia – Overview
- Pipeline product and services with Refractory Acute Myeloid Leukemia – Comparative Analysis
- Refractory Acute Myeloid Leukemia – Therapeutics under progress by Companies
- Refractory Acute Myeloid Leukemia – Therapeutics under Investigation by Universities/Institutes
- Refractory Acute Myeloid Leukemia product and services Glance
- Late phase Products
- Clinical phase Products
- Early phase Products
- Refractory Acute Myeloid Leukemia – product and services under progress by Companies
- Refractory Acute Myeloid Leukemia – product and services under Investigation by Universities/Institutes
- Refractory Acute Myeloid Leukemia – Organizations associated with Therapeutics Development
- 4SC AG
- AbbVie Inc.
- Actinium Pharmaceuticals, Inc.
- Aeglea BioTherapeutics, Inc.
- Agios Pharmaceuticals, Inc.
- Amgen Inc.
- Arog Pharmaceuticals, Inc.
- Array BioPharma Inc.
- Astellas Pharma Inc.
- AVEO Pharmaceuticals, Inc.
- Bellicum Pharmaceuticals, Inc.
- BioLineRx, Ltd.
- Boehringer Ingelheim GmbH
- Boston Biomedical, Inc.
- Bristol-Myers Squibb Company
- Calithera Biosciences, Inc.
- Celgene Corporation
- Eisai Co., Ltd.
- EpiZyme, Inc.
- Exelixis, Inc.
- F. Hoffmann-La Roche Ltd.
- FORMA Therapeutics, Inc.
- Fujifilm Corporation
- GlaxoSmithKline Plc
- GlycoMimetics, Inc.
- Igenica Biotherapeutics, Inc.
- Incyte Corporation
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Johnson & Johnson
- JW Pharmaceutical Corporation
- Karyopharm Therapeutics, Inc.
- Kyowa Hakko Kirin Co., Ltd.
- Les Laboratoires Servier SAS
- MacroGenics, Inc.
- Merck & Co., Inc.
For much more post browse through http://ift.tt/28SUJbO
